Venous Thromboembolism Therapeutics
1. Bevyxxa patent expiration
Treatment: Prophylaxis of pulmonary embolism; Prophylaxis of venous thromboembolism; Inhibiting coagulation; Prophylaxis of venous thrombosis; Preventi...
BEVYXXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8691847 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US6376515 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US8518977 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(5 years ago) | |
| US6835739 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor Xa |
Sep, 2020
(5 years ago) | |
| US7598276 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(9 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA PHARMS INC | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(9 months from now) | |
| US9629831 | PORTOLA PHARMS INC | Benzamides and related inhibitors of factor XA |
Sep, 2020
(5 years ago) | |
| US8404724 | PORTOLA PHARMS INC | Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor |
Mar, 2031
(5 years from now) | |
| US8557852 | PORTOLA PHARMS INC | Methods of using crystalline forms of a salt of a factor Xa inhibitor |
Sep, 2028
(2 years from now) | |
| US8987463 | PORTOLA PHARMS INC | Methods of synthesizing factor Xa inhibitors |
Dec, 2030
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Dosage: CAPSULE
More Information on Dosage
BEVYXXA family patents
2. Eliquis patent expiration
Treatment: Reducing the risk of stroke and systemic embolism; Prophylaxis of pulmonary embolism
ELIQUIS's oppositions filed in EPO
ELIQUIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(10 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6413980 | BRISTOL MYERS SQUIBB | Nitrogen containing heterobicycles as factor Xa inhibitors |
Dec, 2019
(6 years ago) | |
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(5 years from now) | |
|
US6967208 (Pediatric) | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
May, 2027
(1 year, 4 months from now) | |
|
US9326945 (Pediatric) | BRISTOL MYERS SQUIBB | Apixaban formulations |
Aug, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-681) | Mar 03, 2017 |
| New Indication(I-661) | Aug 21, 2017 |
| New Indication(I-690) | Aug 21, 2017 |
| New Indication(I-691) | Aug 21, 2017 |
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
| New Patient Population(NPP) | Apr 17, 2028 |
| New Strength(NS) | Apr 17, 2028 |
| Pediatric Exclusivity(PED) | Oct 17, 2028 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 18 October, 2027
Market Authorisation Date: 17 April, 2025
Dosage: TABLET; TABLET, FOR SUSPENSION
How can I launch a generic of ELIQUIS before it's drug patent expiration?
More Information on Dosage
ELIQUIS family patents
3. Pradaxa patent
expiration
Treatment: Inhibition of thrombin; Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Treatment of venous thrombotic disease
PRADAXA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Dec, 2021
(4 years ago) | |
| US7932273 | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Sep, 2025
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7866474 (Pediatric) | BOEHRINGER INGELHEIM | Film container |
Mar, 2028
(2 years from now) | |
| US6087380 | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Feb, 2018
(7 years ago) | |
| US9925174 | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Jun, 2023
(2 years ago) | |
| US7866474 | BOEHRINGER INGELHEIM | Film container |
Aug, 2027
(1 year, 7 months from now) | |
|
US6087380 (Pediatric) | BOEHRINGER INGELHEIM | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
Jun, 2022
(3 years ago) | |
|
US9925174 (Pediatric) | BOEHRINGER INGELHEIM | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
Dec, 2023
(2 years ago) | |
| US9034822 | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jan, 2031
(5 years from now) | |
|
US7932273 (Pediatric) | BOEHRINGER INGELHEIM | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
Mar, 2026
(a month from now) | |
|
US9034822 (Pediatric) | BOEHRINGER INGELHEIM | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
Jul, 2031
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 19, 2015 |
| New Indication(I-682) | Apr 04, 2017 |
| New Indication(I-683) | Apr 04, 2017 |
| M(M-168) | Nov 20, 2018 |
| New Strength(NS) | Nov 20, 2018 |
| New Indication(I-862) | Jun 21, 2024 |
| New Product(NP) | Jun 21, 2024 |
| Pediatric Exclusivity(PED) | Dec 21, 2024 |
Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient
Market Authorisation Date: 21 June, 2021
Dosage: PELLETS; CAPSULE
How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage
PRADAXA family patents
4. Xarelto patent expiration
Treatment: Reduction in the risk of recurrence of deep vein thrombosis (dvt) and pulmonary embolism; Prophylaxis of deep vein thrombosis (dvt); Treatment of v...
XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(1 year, 4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7585860 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US7592339 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Dec, 2020
(5 years ago) | |
| US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(1 year, 1 month ago) | |
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(8 years from now) | |
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(13 years from now) | |
|
US7157456 (Pediatric) | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Feb, 2025
(10 months ago) | |
|
US9415053 (Pediatric) | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
May, 2025
(7 months ago) | |
|
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(8 years from now) | |
|
US10828310 (Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents